Hyaluron Filler Containing Lidocaine on a CPM Basis for Lip Augmentation: Reports from Practical Experience

Abstract

Lip augmentation with hyaluronic acid fillers is established. As monophasic polydensified hyaluronic acid products with variable density, CPM-HAL1 (Belotero Balance Lidocaine, Merz Aesthetics, Raleigh, NC) and CPM-HAL2 (Belotero Intense Lidocaine, Merz Aesthetics, Raleigh, NC) are qualified for beautification and particularly natural-looking rejuvenation, respectively. The aim of this article was to assess the handling and outcome of lip augmentation using the lidocaine-containing hyaluronic acid fillers, CPM-HAL1 and CPM-HAL2. Data were documented from patients who received lip augmentation by means of beautification and/or rejuvenation using CPM-HAL1 and/or CPM-HAL2. Observation period was 4 months, with assessment of natural outcome, evenness, distribution, fluidity, handling, malleability, tolerability, as well as patient satisfaction and pain. A total of 146 patients from 21 German centers participated. Physicians rated natural outcome and evenness as good or very good for more than 95% of patients. Distribution, fluidity, handling, and malleability were assessed for both fillers as good or very good in more than 91% of patients. At every evaluation point, more than 93% of patients were very or very much satisfied with the product. A total of 125 patients (85.6%) experienced transient injection-related side effects. Pain intensity during the procedure was mild (2.72 ± 1.72 on the 0–10 pain assessment scale) and abated markedly within 30 minutes (0.42 ± 0.57). Lip augmentation with hyaluronic acid fillers produced a long-term cosmetic result. Due to the lidocaine content, procedural pain was low and transient. Accordingly, a high degree of patient satisfaction was achieved that was maintained throughout the observation period.

Keywords

lip augmentation - hyaluronic acid filler - CPM-HA - lidocaine

This article is reprinted from Fischer T, Sattler G, Gauglitz G. Lidocainhaltiger Hyaluronfiller auf CPM®-Basis zur Lippenaugmentation: Erfahrungsberichte aus der Praxis. Der Hautarzt 2016; April 6 (Epub ahead of print); doi: 10.1007/s00105-016-3779-1. © Springer-Verlag Berlin Heidelberg 2016. With permission of Springer.

• References

• 1 Heckmann M, Teichmann B, Schröder U, Sprengelmeyer R, Ceballos-Baumann AO. Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. J Am Acad Dermatol 2003; 49 (2) 213-216
• 2 Lewis MB, Bowler PJ. Botulinum toxin cosmetic therapy correlates with a more positive mood. J Cosmet Dermatol 2009; 8 (1) 24-26
• 3 Bogle MA, Arndt KA, Dover JS , et al. Evaluation of the aging face. In: Kaminer MS, Dover JS, Arndt KA. eds. Atlas of Cosmetic Surgery. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009: 37-43
• 4 Sarnoff DS, Saini R, Gotkin RH. Comparison of filling agents for lip augmentation. Aesthet Surg J 2008; 28 (5) 556-563
• 5 Eccleston D, Murphy DK. Juvéderm® Volbella™ in the perioral area: a 12-month prospective, multicenter, open-label study. Clin Cosmet Investig Dermatol 2012; 5: 167-172
• 6 Kühne U, Imhof M, Kirchmeir M, Howell DJ. Five-year retrospective review of safety, injected volumes, and longevity of the hyaluronic acid Belotero Basic for facial treatments in 317 patients. J Drugs Dermatol 2012; 11 (9) 1032-1035
• 7 Philipp-Dormston WG, Hilton S, Nathan M. A prospective, open-label, multicenter, observational, postmarket study of the use of a 15 mg/mL hyaluronic acid dermal filler in the lips. J Cosmet Dermatol 2014; 13 (2) 125-134
• 8 Raspaldo H, Chantrey J, Belhaouari L, Saleh R, Murphy DK. Juvéderm volbella with lidocaine for lip and perioral enhancement: a prospective, randomized, controlled trial. Plast Reconstr Surg Glob Open 2015; 3 (3) e321
• 9 Kablik J, Monheit GD, Yu L, Chang G, Gershkovich J. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg 2009; 35 (Suppl. 01) 302-312
• 10 Brandt FS, Cazzaniga A. Hyaluronic acid gel fillers in the management of facial aging. Clin Interv Aging 2008; 3 (1) 153-159
• 11 Prager W, Steinkraus V. A prospective, rater-blind, randomized comparison of the effectiveness and tolerability of Belotero® Basic versus Restylane® for correction of nasolabial folds. Eur J Dermatol 2010; 20 (6) 748-752
• 12 Smith L, Cockerham K. Hyaluronic acid dermal fillers: can adjunctive lidocaine improve patient satisfaction without decreasing efficacy or duration?. Patient Prefer Adherence 2011; 5 (5) 133-139
• 13 Micheels P, Sarazin D, Besse S, Sundaram H, Flynn TC. A blanching technique for intradermal injection of the hyaluronic acid Belotero. Plast Reconstr Surg 2013; 132 (4) (Suppl. 02) 59S-68S
• 14 Glogau RG, Kane MA. Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid gel dermal fillers. Dermatol Surg 2008; 34 (Suppl. 01) S105-S109
• 15 Weinkle S. Injection techniques for revolumization of the perioral region with hyaluronic acid. J Drugs Dermatol 2010; 9 (4) 367-371
• 16 Carruthers A, Carruthers J, Hardas B , et al. A validated lip fullness grading scale. Dermatol Surg 2008; 34 (Suppl. 02) S161-S166
• 17 Buntrock H, Reuther T, Prager W, Kerscher M. Efficacy, safety, and patient satisfaction of a monophasic cohesive polydensified matrix versus a biphasic nonanimal stabilized hyaluronic acid filler after single injection in nasolabial folds. Dermatol Surg 2013; 39 (7) 1097-1105
• 18 Prager W, Wissmueller E, Havermann I , et al. A prospective, split-face, randomized, comparative study of safety and 12-month longevity of three formulations of hyaluronic acid dermal filler for treatment of nasolabial folds. Dermatol Surg 2012; 38 (7, Pt 2): 1143-1150